 MALVERN, Pa., May 13, 2021 GLOBE NEWSWIRE -- Baudax Bio, Inc. NASDAQ:BXRX the Company, a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that Institutional Shareholder Services, Inc. ISS, the leading global independent proxy advisory firm, has recommended that Baudax Bio shareholders vote FOR Proposal 3, which seeks to amend the Companys Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock from 100 million shares to 190 million shares. The Annual Meeting is expected to resume with respect to Proposal 3 on June 3, 2021 at 10:00 a.m. ET and will continue to be held virtually at 